Journal article
Integrative analysis of clinicopathological features defines novel prognostic models for mantle cell lymphoma in the immunochemotherapy era: a report from The North American Mantle Cell Lymphoma Consortium
Journal of hematology and oncology, Vol.16(1), 122
12/16/2023
DOI: 10.1186/s13045-023-01520-7
PMCID: PMC10725579
PMID: 38104096
Abstract
Background
Patients with mantle cell lymphoma (MCL) exhibit a wide variation in clinical presentation and outcome. However, the commonly used prognostic models are outdated and inadequate to address the needs of the current multidisciplinary management of this disease. This study aims to investigate the clinical and pathological features of MCL in the immunochemotherapy era and improve the prognostic models for a more accurate prediction of patient outcomes.
Methods
The North American Mantle Cell Lymphoma Project is a multi-institutional collaboration of 23 institutions across North America to evaluate and refine prognosticators for front-line therapy. A total of 586 MCL cases diagnosed between 2000 and 2012 are included in this study. A comprehensive retrospective analysis was performed on the clinicopathological features, treatment approaches, and outcomes of these cases. The establishment of novel prognostic models was based on in-depth examination of baseline parameters, and subsequent validation in an independent cohort of MCL cases.
Results
In front-line strategies, the use of hematopoietic stem cell transplantation was the most significant parameter affecting outcomes, for both overall survival (OS, p < 0.0001) and progression-free survival (PFS, p < 0.0001). P53 positive expression was the most significant pathological parameter correlating with inferior outcomes (p < 0.0001 for OS and p = 0.0021 for PFS). Based on the baseline risk factor profile, we developed a set of prognostic models incorporating clinical, laboratory, and pathological parameters that are specifically tailored for various applications. These models, when tested in the validation cohort, exhibited strong predictive power for survival and showed a stratification resembling the training cohort.
Conclusions
The outcome of patients with MCL has markedly improved over the past two decades, and further enhancement is anticipated with the evolution of clinical management. The innovative prognostic models developed in this study would serve as a valuable tool to guide the selection of more suitable treatment strategies for patients with MCL.
Details
- Title: Subtitle
- Integrative analysis of clinicopathological features defines novel prognostic models for mantle cell lymphoma in the immunochemotherapy era: a report from The North American Mantle Cell Lymphoma Consortium
- Creators
- Julie M. Vose - University of Nebraska Medical CenterKai Fu - Roswell Park Cancer InstituteLu Wang - Yantai UniversityAdnan Mansoor - University of CalgaryDouglas Stewart - University of CalgaryHongxia Cheng - Shandong Provincial HospitalLynette Smith - University of Nebraska Medical CenterJi Yuan - Rochester, MN USAHina Naushad Qureishi - University of Nebraska Medical CenterBrian K. Link - University of IowaMelissa H. Cessna - Intermountain Medical CenterPaul M. Barr - University of Rochester Medical CenterBrad S. Kahl - Washington University in St. LouisMatthew S. Mckinney - Duke Medical CenterNadia Khan - Fox Chase Cancer CenterRanjana H. Advani - Stanford, CA USAPeter Martin - Cornell UniversityAndre H. Goy - Hackensack University Medical CenterTycel J. Phillips - University of MichiganAmitkumar Mehta - University of Alabama at BirminghamManali Kamdar - University of Colorado DenverMichael Crump - Princess Margaret Cancer CentreBarbara Pro - Northwestern UniversityChristopher R. Flowers - The University of Texas MD Anderson Cancer CenterCaron A. Jacobson - Dana-Farber Cancer InstituteSonali M. Smith - University of ChicagoDeborah M. Stephens - Huntsman Cancer InstituteVeronika Bachanova - University of MinnesotaZhaohui Jin - Mayo ClinicShishou Wu - Yuhuangding HospitalFrancisco Hernandez-Ilizaliturri - Buffalo, NY USAPallawi Torka - Memorial Sloan Kettering Cancer CenterAndrea Anampa-Guzmán - Roswell Park Cancer InstituteFarshid Kashef - University at Buffalo, State University of New YorkXing Li - Roswell Park Cancer InstituteSunandini Sharma - University of Nebraska Medical CenterTimothy C. Greiner - University of Nebraska Medical CenterJames O. Armitage - University of Nebraska Medical CenterMatthew Lunning - University of Nebraska Medical CenterDennis D. Weisenburger - University of Nebraska Medical CenterRobert G. Bociek - University of Nebraska Medical CenterJaveed Iqbal - University of Nebraska Medical CenterGuohua Yu - Yuhuangding HospitalChengfeng Bi - University of Nebraska Medical CenterNorth American Mantle Cell Lymphoma Consortium
- Resource Type
- Journal article
- Publication Details
- Journal of hematology and oncology, Vol.16(1), 122
- DOI
- 10.1186/s13045-023-01520-7
- PMID
- 38104096
- PMCID
- PMC10725579
- NLM abbreviation
- J Hematol Oncol
- ISSN
- 1756-8722
- eISSN
- 1756-8722
- Publisher
- BioMed Central
- Grant note
- name: University of Nebraska Foundation
- Language
- English
- Date published
- 12/16/2023
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
- Record Identifier
- 9984532195002771
Metrics
17 Record Views